Cuban Lung Cancer Vaccine Receives Creativity and Technical Innovation Award 2015

Editado por Ivan Martínez
2015-11-19 14:23:08

Pinterest
Telegram
Linkedin
WhatsApp

Havana, November 19 (RHC)-- Cuba's Industrial Property Office has presented the Cuban advanced lung cancer vaccine, developed by the Havana-based Molecular Immunology Center, with the Creativity and Technical Innovation Award 2015.

Registered in Cuba since 2012, the product called Vaxira, has a very favorable impact of the patients' survival rate and quality of life, while no side-effects have been reported.

Vaxira is now registered in 17 countries. Studies are currently underway to assess its impact on patients suffering from breast and ovarian cancers.



Comentarios


Deja un comentario
Todos los campos son requeridos
No será publicado
captcha challenge
up